Table 1 Demographics, treatment and patient reported outcomes in four surveys of RF positive patients in the Malmö RA population
1997 | 2002 | 2005 | 2009 | |
|---|---|---|---|---|
N | 668 | 438 | 517 | 454 |
Disease duration years, mean (SD) | 15.0 (13.6) | 16.7 (12.5) | 15.8 (12.5) | 17.2 (12.1) |
Female sex | 497 (74%) | 321 (73%) | 368 (71%) | 331 (73%) |
Age; years, mean | 61.9 (14.1) | 63.9 (13.6) | 62.9 (14.2) | 63.8 (13.4) |
Current treatment proportion (95 % CI) | ||||
Corticosteroids | 19% (16-22) | 30% (26-35) | 26 % (23-30) | 31 % (27-35) |
Biologic | 0 | 16% (12-19) | 23 % (19-27) | 29 % (25-33) |
Methotrexate | 20% (17-23) | 44% (40-49) | 56 % (52-60) | 58 % (54-63) |
Patient reported outcomes mean (95% CI) unless otherwise noted | ||||
HAQ* | 1.12 (0.50-1.75) | 1.00 (0.50-1.62) | 0.88 (0.38-1.38) | 0.88 (0.38-1.5) |
VAS global | 44.8 (42.3-47.4) | 40.0 (37.6-42.4) | 41.8 (39.6-44.1) | 37.6 (35.2-40.0) |
VAS pain | 46.3 (43.7-48.9) | 41.1 (38.8-43.5) | 40.8 (38.6-43.0) | 38.2 (35.8-40.7) |
SF-36 PCS | 32.1 (31.0-33.1) | 33.2 (32.2-34.4) | 34.6 (33.6-35.7) | 35.2 (34.0-36.4) |
SF-36 MCS | 45.4 (44.0-46.7) | 46.7 (45.4-48.1) | 47.9 (46.7-49.0) | 47.1 (45.9-48.3) |